The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Triple M overlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database.
 
Abdul Rafeh Naqash
Honoraria - NGM Biopharmaceuticals
Consulting or Advisory Role - foundation me
Travel, Accommodations, Expenses - American Society for Radiation Oncology; ASCO; Binacea; Foundation Medicine; Jazz Pharmaceuticals (Inst); Society for Immunotherapy of Cancer
 
Hassan Mohammed Abushukair
No Relationships to Disclose
 
Eman Alghamdi
No Relationships to Disclose
 
Mehak Masood Laharwal
No Relationships to Disclose
 
Hafsa M Gundroo
No Relationships to Disclose
 
Aik-choon Tan
Employment - Bristol-Myers Squibb/Celgene/Juno (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene/Juno (I)
 
Pauline Funchain
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai; GigaGen; Merck; Novartis; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Taiho Oncology (Inst)
(OPTIONAL) Uncompensated Relationships - Nirvana Healthcare Ventures
 
Noha Abdel-Wahab
Honoraria - ChemoCentryx
Consulting or Advisory Role - ChemoCentryx
 
Elad Sharon
Consulting or Advisory Role - D.E. Shaw Research; Mallinckrodt/Therakos
 
Douglas Buckner Johnson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Mosaic ImmunoEngineering; Novartis; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Abatacept for the use of immune related adverse events.; Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Amin Nassar
No Relationships to Disclose
 
Fawaz F Al-Harbi
No Relationships to Disclose